The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2022 | How has the role of transplant changed with the introduction of CAR-T therapy?
Michele Cavo, MD, PhD, Bologna University School of Medicine, Bologna, Italy, shares some insights into how the role of transplantation has changed with the introduction of CAR-T therapy. Prof. Cavo explains that head-to-head comparison trials are still needed to evaluate CAR-T versus transplant upfront, and also mentions the promise that CAR-T therapy has provided for high-risk patients and those with relapsed disease. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
